Massive Eye Drop Recall: Sterility Concerns Spur 3.1 Million Bottle Pull

More than 3.1 million bottles of over-the-counter eye drops have been recalled after manufacturer K.C. Pharmaceuticals flagged potential sterility issues, according to an announcement by the Food and Drug Administration (FDA) dated March 3. The products were sold through major US retailers, including Walgreens and CVS, and the agency said consumers who purchased the affected eye drops should stop using them.

The FDA classified the action as a “Class II” recall . Under that designation, the agency said the products may lead to temporary or medically reversible adverse health consequences, while the probability of serious harm is considered remote. The FDA’s notice ties the recall to sterility concerns rather than a confirmed contamination event in the announcement.

The recall covers eight distinct brands manufactured by K.C. Pharmaceuticals. The largest single lot cited involves more than 1 million bottles of Dry Eye Relief Eye Drops. Distribution for that product included retailers such as Rite Aid, H-E-B, and Harris Teeter, according to the FDA’s announcement.

Other recalled products named by the FDA include Artificial Tears Sterile Lubricant Eye Drops, Sterile Eye Drops Original Formula, and Sterile Eye Drops Redness Lubricant. The notice said these items were sold across a mix of pharmacy chains and general merchandise stores, widening the potential consumer footprint beyond a single retailer network.

The FDA’s update also pointed to a prior episode in 2023, when a separate recall involving a different manufacturer was linked to bacterial contamination. While the current action involves K.C. Pharmaceuticals and is described as a sterility concern, the reference highlights continued attention on manufacturing controls and quality assurance for non-prescription ophthalmic products.

For retailers and suppliers, the recall creates immediate operational steps, including removing affected inventory and managing customer notifications and returns. For consumers, the agency’s guidance is straightforward: discontinue use of the recalled eye drops, reflecting the FDA’s view that adverse effects are possible even if severe outcomes are unlikely under the Class II framework.

What remains unclear from the FDA announcement is the specific mechanism behind the sterility concern, including whether it relates to production, packaging, or handling, and whether any adverse events were reported. The recall nonetheless underscores ongoing regulatory scrutiny of over-the-counter eye care products aimed at protecting consumer safety in a category that is widely used and often purchased without medical supervision.